INSILICO (03696.HK): Nominates GIPR antagonist ISM1354 as PCC

NewTimeSpace News: On 30 September 2026, InSilico Medicine Cayman TopCo (stock code: 03696.HK) announced that, driven by its proprietary generative AI platform, it has nominated ISM1354, a potentially best-in-class next-generation small-molecule GIPR antagonist, as a preclinical candidate compound (PCC) for obesity, type 2 diabetes and related conditions, with potential expansion into cardiovascular disease.

In January this year, the Company nominated another GIPR antagonist, ISM0676, which achieved up to 31.3% weight loss in humanized mouse models when combined with semaglutide. The latest PCC retains good drug-like properties and adds multi-dimensional optimization in pharmacokinetics (PK) and safety. The Company has nominated 10 PCCs in the first nine months of 2026, a record annual pipeline output, bringing its total PCC nominations since 2021 to 34. 

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.